Q-omics provides the consensus-scored MMEL1 profile across patient tissues and cancer cell-line models. MMEL1 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, MMEL1 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, MMEL1 RNA expression shows 15,448 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight MESO, THCA, and THYM as cancer lineages where MMEL1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MMEL1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MMEL1 survival associations across molecular data types. MMEL1 RNA expression shows survival associations in the most cancer types (18), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MMEL1 RNA expression–survival associations across cancer types. High MMEL1 expression shows unfavorable associations in LGG and UCS, but favorable associations in MESO, BLCA, ACC and BRCA. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for MMEL1 RNA expression.
This table summarizes MMEL1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for MMEL1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MMEL1 shows lower tumor expression in THCA, KIRC, LUSC and HNSC and higher tumor expression in BRCA and CHOL. The THCA box plot shows higher MMEL1 RNA expression in normal versus tumor tissue (log2 FC = −1.327, t-test p < 0.001).
This table shows molecular features associated with MMEL1 in patient tissues and cancer cell lines. In patient samples, MMEL1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, MMEL1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BREAST.
